Milestone Pharmaceuticals Inc.


Milestone Pharmaceuticals is a patient-centric, clinical-stage biopharmaceutical company dedicated to developing treatments for episodic cardiovascular conditions such as paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR). The company focuses on self-administration treatments that can be used outside of emergency or hospital settings, aiming to fill unmet medical needs and improve patient quality of life. Their lead investigational product, etripamil, is a nasal spray calcium channel blocker designed for rapid, at-home treatment of these conditions. Milestone is committed to advancing scientific discovery through clinical trials and research, with a mission to empower patients to manage their episodes wherever and whenever they occur.

Industries

biotechnology
health-care
therapeutics

Nr. of Employees

small (1-50)

Milestone Pharmaceuticals Inc.


Products

Investigational intranasal small-molecule calcium channel blocker for at-home acute treatment of episodic cardiovascular events

An investigational, intranasally administered small-molecule calcium channel blocker developed for rapid, outpatient self-administration to terminate paroxysmal supraventricular tachycardia (PSVT) and to control atrial fibrillation with rapid ventricular rate (AFib-RVR). Not approved for any indication.


Services

Clinical trial execution and patient access support

Management of clinical studies for acute, episodic cardiovascular conditions and programs to support patient recruitment and trial participation.

Patient education and advocacy program development

Creation and operation of condition-specific patient resources and educational websites to support disease management and trial awareness.

Expertise Areas

  • Clinical trial management for cardiovascular indications
  • Small-molecule drug discovery and optimization
  • Intranasal drug delivery and formulation
  • Regulatory submission & health authority interactions
  • Show More (3)

Key Technologies

  • Intranasal drug delivery
  • Small-molecule calcium channel blockade (mechanism-driven design)
  • Rapid-onset, short half-life pharmacokinetic profiles
  • Phase 2–3 clinical development
  • Show More (2)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.